Biogen Idec, the company behind several of today’s most widely sold multiple sclerosis drugs, has been developing a novel treatment for Alzheimer’s disease, called BIIB037, which has shown great potential in blocking beta amyloid — one of the hallmarks of this common form of dementia…
A large study entitled “Genome-wide studies of verbal declarative memory in non-demented older people: the CHARGE consortium” was recently published in the journal Biological Psychiatry and sought to identify the genetics of memory function in older individuals. One of the most essential aspects of human cognition is the…
The Texas A&M Health Science Center College of Medicine recently launched a new initiative against Alzheimer’s Disease that aims to encourage the use of the Texas Alzheimer’s Research and Care Consortium’s (TARCC) large patient cohort. The TARCC Investigator Grant Program will be awarding a total of five inaugural grants worth $50,000 each, and two grants…
In a new study entitled “Metabotropic P2Y1 receptor signaling mediates astrocytic hyperactivity in vivo in an Alzheimer’s disease mouse model” published in Nature Communications, Andrea Delekate and colleagues examined the astrocytic network underlying pathways that may be implicated in Alzheimer’s disease (AD), and provide solid evidence for…
Biopharmaceutical company Anavex Life Sciences Corp. recently presented encouraging results from their phase 1 clinical trial, a study testing the company’s lead investigational oral treatment for Alzheimer’s disease, Anavex 2-73, at CNS Summit 2014 in Boca Raton, Florida. After assessing the drug’s safety and effectiveness, the medication…
A recent review from Schichun Tu and colleagues entitled “Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease” was published this week in the journal Molecular Neurodegeneration. The aim of the study was to discuss the state of current evidence suggesting that the synaptic loss found in…
The Alzheimer’s Foundation of America (AFA) is organizing a public awareness campaign to remember the importance of keeping memories alive. As part of the campaign, they are asking people to share beloved memories by posting old photos on their social networks using the hashtag #RememberTogether. The Remember Together campaign is one of…
In a research article entitled “Primary age-related tauopathy (PART): a common pathology associated with human aging,” recently published in the Acta Neuropathologica, researchers uncovered new insights into an Alzheimers-related memory disorder. This multi-institutional study, co-led by…
The Cigna Foundation announced that is awarding a $196,000 World of Difference grant to the Alzheimer’s Association to support the development of a program dedicated to help early stage patients currently diagnosed with Alzheimer’s and other forms of dementia. LiveWell interactive E-Learning Program is meant to be a…
A novel, potentially disease-modifying treatment for Alzheimer’s disease is set to begin a Phase 2a clinical trial, designed to evaluate efficacy over a time frame of 6 months, across 7 study sites in Australia. ANAVEX 2-73, a pipeline product of Anavex Life Sciences Corp.,…
Get regular updates to your inbox.